SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending as the crypto community discusses its potential to reach new all-time highs, fueled by optimism around "Uptober" and potential impacts from the US government shutdown. Community members are sharing bullish predictions and analyzing technical indicators, while also debating the influence of large institutional players. The conversation includes discussion of Bitcoin's role as a safe haven asset amid economic uncertainty.

Zcash is a decentralized and open-source cryptocurrency that offers privacy and selective transparency of transactions. Zcash payments are published on a public blockchain, but the sender, recipient, and amount of a transaction remain private.  Zcash is based on peer-reviewed cryptographic research, and built by a security-specialized engineering team on an open source platform based on Bitcoin Core's battle-tested codebase. Our improvement over Bitcoin is the addition of privacy. Zcash uses advanced cryptographic techniques, namely zero-knowledge proofs, to guarantee the validity of transactions without revealing additional information about them.  How Zcash works  Zcash encrypts the contents of shielded transactions. Since the payment information is encrypted, the protocol uses a novel cryptographic method to verify their validity.  Zcash uses a zero-knowledge proof construction called a zk-SNARK, developed by our team of experienced cryptographers based on recent breakthroughs in cryptography. These constructions allow the network to maintain a secure ledger of balances without disclosing the parties or amounts involved. Instead of publicly demonstrating spend-authority and transaction values, the transaction metadata is encrypted and zk-SNARKs are used to prove that nobody is cheating or stealing.  Zcash also enables users to send public payments which work similarly to Bitcoin. With the support for both shielded and transparent addresses, users can choose to send Zcash privately or publicly. Zcash payments sent from a shielded address to a transparent address reveal the received balance, while payments from a transparent address to a shielded address protect the receiving value.   Check out CoinBureau for guide on What is ZCash.

Zcash

Zcash is trending as the crypto community discusses its recent price action and potential, focusing on its privacy features and capped supply akin to Bitcoin. Some anticipate significant gains, drawing attention to its upcoming halving event and historical all-time high, while others are wary of potential pullbacks. Discussions also highlight its integration with various platforms and wallets, emphasizing its growing utility in private transactions.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending due to controversy sparked by Elon Musk's call to cancel subscriptions over concerns about transgender-related content in kids' shows, leading to a polarized debate within the community. Some users report cancelling their subscriptions in response, while others criticize the call for a boycott and highlight the prevalence of diverse content across streaming platforms. Broader discussions include the impact of potential boycotts, content quality, and the company's overall value.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending as traders eye potential breakout momentum and AI chip strength, while keeping a close watch on the $165 resistance level. Community members are debating whether the stock will follow the sector's bullish trend or if it will disappoint, with some discussing a potential partnership with Intel. Bullish sentiment is fueled by AI prospects and collaborations with IBM and Oracle.

Rezolve AI Plc operates in the mobile commerce industry with its cutting-edge engagement platform powered by artificial intelligence and machine learning. It develops AI-based mobile commerce and engagement solutions, simplifying the purchasing process by providing relevant information and facilitating seamless transactions with a single tap. The company enables retailers, brands, and manufacturers to create dynamic connections with consumers across mobile and desktop devices. Rezolve Ai was founded in 2016 and is headquartered in London, the United Kingdom.

Rezolve AI PLC .

Rezolve AI Limited

Rezolve AI ($RZLV) is trending amid discussions about its recent earnings report and raised ARR guidance, with community members debating the legitimacy of partnerships and revenue projections. Some are optimistic about long-term growth and potential short squeezes, while others express concerns about the company's accounting practices and CEO's history, pointing to a recent short seller report. The stock's high trading volume and volatile price action reflect the divided sentiment.

Aptos is a new, independent high-performance PoS Layer 1 project focused on delivering the safest and most scalable Layer 1 blockchain in the world. The Aptos blockchain leverages the Move programming language and the Move VM for application development, which are created and optimized for blockchain use cases.The team is comprised of the original creators, researchers, designers, and builders of Diem, the blockchain that was first built to serve this purpose. Aptos raised $200m from a16z, Multicoin, Binance and others. Aptos launched Devnet in mid March, incentivized testnet in late May and targets Q3 for mainnet launch.

Aptos

Aptos (APT) is trending due to growing excitement around its potential for stablecoin adoption and real-world asset (RWA) tokenization, with the community actively discussing its partnerships and integrations, including those involving LayerZero's WBTC-OFT. Some traders anticipate a price bounce from the current support levels, while others compare its scalability and accessibility to other Layer 1 blockchains like Keeta.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. It provides online news services where users can select and rank web content. The firm also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

RDDT is trending downwards, driven by concerns over ChatGPT's decreased reliance on Reddit data, sparking worries about future ad revenue and user engagement; The community is actively debating whether this dip is a buying opportunity or a sign of deeper issues, with some citing the stock's high valuation and political leanings as additional factors; Despite the recent pullback, some investors remain bullish, pointing to Reddit's potential in AI and strong fundamentals.

Angel Studios, Inc. is a values-based distribution company for stories that amplify light to mainstream audiences. The company is headquartered in Provo, UT.

Angel Studios Inc. - Ordinary Shares - Class A

Angel Studios Inc

ANGX is trending due to its recent public debut and connection to Elon Musk's Gigafund, sparking community excitement and speculation about its potential as a disruptor in the streaming space. Discussions revolve around its unique content strategy, strong community backing, and comparisons to Netflix, with some anticipating significant growth while others remain skeptical. The community is closely watching for news and catalysts that could drive the stock's price.

iShares Bitcoin Trust ETF - iShares Bitcoin Trust Beneficial Interest

iShares Bitcoin ETF

IBIT is trending as the community discusses potential upside driven by large call sweeps and significant net inflows, while also considering potential downside risks. Talk centers around the ETF's correlation with Bitcoin's price movements, the influence of potential rate cuts, and the broader market sentiment towards crypto assets. Some see IBIT as a simpler way to get exposure to Bitcoin compared to holding the cryptocurrency directly.

Medical Properties Trust, Inc. is a self-advised real estate investment trust. It engages in the investment, acquisition, and development of net-leased healthcare facilities. Its property portfolio includes rehabilitation hospitals, long-term acute care hospitals, ambulatory surgery centers, hospitals for women and children, regional and community hospitals, medical office buildings, and other single-discipline facilities. The company was founded by Edward K. Aldag Jr., R. Steven Hamner, Emmett E. McLean, and William Gilliard McKenzie in 2003 and is headquartered in Birmingham, AL.

Medical Properties Trust Inc

MPW is trending as investors discuss a potential short squeeze given its high short interest and improving financials, with some pointing to a "golden cross" technical indicator and upcoming earnings as potential catalysts. Community members are debating whether the short thesis is still valid, citing the company's book value and potential for shareholder initiatives. Some are eagerly anticipating a rise in stock price while others remain skeptical.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

General Motors (GM) on Wednesday said that it delivered 710,347 vehicles in the U.S. in the third quarter (Q3), marking a growth of 7.7% year-over-year.Electric vehicle <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investor.gm.com/static-files/501fc28d-057f-413a-a4cc-0a8a7eaa8257">sales</a> in the quarter hit a fresh record of 66,501 units, marking a growth of 107%, as customers rushed to make their EV purchase before the expiry of the federal tax credit of $7,500 on September 30. The Chevrolet Equinox EV was the company’s best-selling EV in the quarter with 25,085 units delivered. Luxury segment EVs from GM’s Cadillac brand, including the Lyriq, Optiq, and Vistiq, also recorded significant delivery numbers despite higher price points.Chevrolet was the company’s best-selling brand in the quarter, with deliveries rising 8.3% to 710,347 units in the three months through the end of September. While the company’s Cadillac and GMC brands also recorded delivery growth in the quarter, Buick deliveries dropped a steep 14%. GMC is on pace for its best year ever, the company noted. Cadillac, meanwhile, recorded its best third quarter since 2013.Certain models across brands, such as the GMC Terrain, Chevrolet Equinox, Chevrolet Traverse, and Buick Envista, had their best-ever third-quarter sales, the company added. The firm also noted that its fleet business, called GM Evolve, reported a 20% increase in sales in the third quarter.<a href="https://stocktwits.com/symbol/GM">GM shares</a> rose 1% at the time of writing. On Stocktwits, retail sentiment around GM stock fell from ‘extremely bullish’ to ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.GM stock is up by 15% this year and by 37% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/stellantis-expands-partnership-with-mistral-ai-amid-tough-ai-push/chCYBIDR3aU">Stellantis Expands Partnership With Mistral AI Amid Tough AI Push</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of General Motors is seen on a smartphone screen with a steering wheel in the background. (Photo Illustration by Serene Lee/SOPA Images/LightRocket via Getty Images)

General Motors Reports 7.7% Growth In Q3 Auto Sales In US

Electric vehicle sales in the quarter hit a fresh record of 66,501 units as customers rushed to make their EV purchase before the expiry of the federal tax credit of $7,500 on September 30.

Equity

Electric vehicle sales in the quarter hit a fresh record of 66,501 units as customers rushed to make their EV purchase before the expiry of the federal tax credit of $7,500 on September 30.



Jefferies upgraded Carvana (CVNA) to ‘Buy’ from ‘Hold’ on Wednesday, sending shares of the company rallying over 1% in the pre-market session despite weakness in the broader market stemming from the uncertainty around the U.S. government shutdown.The analyst also hiked the price target on the stock to $475, up from $385.. The new price target represents an upside of about 26% from the stock’s last closing price on Tuesday.The firm says the results of its consumer survey, web scape, and capacity analysis suggest Carvana will continue to deliver elevated growth and upside to consensus estimates. In addition, the company's fixed cost leverage will help supplement its revenue growth, supporting further expansion in unit economics and "peer-high" Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) growth, the analyst told investors in a research note, as per TheFly.Jefferies further believes Carvana is best positioned to benefit from a "nascent shift to digital in the massive $800B used car market."On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CVNA">CVNA stock</a> fell to ‘extremely bearish’ from ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:573/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_01_at_7_42_49_AM_png_78437c581b.webp" alt="CVNA's Sentiment Meter and Message Volume as of 7:43 a.m. ET on Oct. 01, 2025 | Source: Stocktwits" width="573" height="62"><figcaption>CVNA's Sentiment Meter and Message Volume as of 7:43 a.m. ET on Oct. 01, 2025 | Source: Stocktwits</figcaption></figure>On Tuesday, Carvana had announced the launch of same-day delivery in the greater San Francisco Bay Area on the heels of Seattle, the Greater Chicago Area, and other regions, in a bid to raise its appeal to customers in the used car market. With Carvana, customers can find a car, get financing, trade in, and complete a purchase entirely online.In the second quarter (Q2) through the end of June, Carvana sold 143,280 retail units, marking a growth of 41% year-over-year, for a total revenue of $4.84 billion, an all-time quarterly record. The company said in July that it expects a sequential increase in retail units sold in the third quarter (Q3) as well.According to data from Koyfin, 14 of the 22 analysts covering CVNA rate it ‘Buy’ or higher, while seven rate it ‘Hold’ and one ‘Sell.’ The average price target on the stock is $421.95, representing an upside of nearly 12% from the last closing price.CVNA stock is up by 86% this year and has more than doubled its value over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-hikes-model-y-model-3-lease-prices-in-us-after-ev-tax-credit-expiry/chCY2ZTR3aW">Tesla Hikes Model Y And Model 3 Lease Prices In US After EV Tax Credit Expiry</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Carvana logo is seen displayed on a smartphone screen.

Carvana Stock Rallies Pre-Market After Jefferies’s Upgrade, Price Target Hike

Jefferies’s new price target represents an upside of about 26% from the stock’s last closing price on Tuesday. 

Amgen (AMGN) on Friday announced a $650 million expansion of its U.S. manufacturing network, on the heels of President Trump’s latest pharmaceutical tariff announcement.Trump said in a post on Truth Social on Thursday that the United States will impose a 100% tariff on branded and patented pharmaceutical products starting October 1 unless manufacturers are actively building plants in the country.Amgen <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.amgen.com/newsroom/press-releases/2025/09/amgen-announces-650m-expansion-of-us-manufacturing-creating-hundreds-of-new-jobs">said</a> on Friday that the planned investment will support increased drug production at the company's biologics manufacturing facility in Juncos, Puerto Rico. The investment is also expected to create about 750 jobs, including construction roles and skilled manufacturing jobs. According to Amgen, the company has invested more than $40 billion in U.S. manufacturing and research and development since late 2017.Earlier this year, the company announced a $900 million expansion of its Ohio manufacturing facility, which followed a late-2024 announcement of a $1 billion expansion to establish a second drug substance manufacturing facility in North Carolina.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AMGN">AMGN stock</a> fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:622/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_26_at_1_54_57_PM_png_99b99c433b.webp" alt="AMGN's Sentiment Meter and Message Volume as of 1:55 p.m. ET on Sept. 26, 2025 | Source: Stocktwits" width="622" height="62"><figcaption>AMGN's Sentiment Meter and Message Volume as of 1:55 p.m. ET on Sept. 26, 2025 | Source: Stocktwits</figcaption></figure>Jefferies analyst Akash Tewari stated on Friday that Trump’s tariffs may not have a material impact on pharmaceutical companies, as several large-cap pharmaceutical firms have already announced plans to establish U.S. manufacturing facilities.A Stocktwits user echoed the analyst’s sentiment, stating that Amgen will also likely be unaffected by the tariffs.<stembedurl>https://stocktwits.com/BobBijawklah/message/630132763</stembedurl>AMGN stock is up 4% this year and down by about 15% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bioaffinity-technologies-stock-surge-over-cypath-lung-case-studies/chDVjeMR3ea">bioAffinity Technologies Stock Surged A Whopping 79% Today – Here’s An Important Update</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The company logo and the lettering of the biotechnology company Amgen can be seen on the facade of the company's headquarters in Munich (Bavaria) on January 14, 2025. Photo: Matthias Balk/dpa (Photo by Matthias Balk/picture alliance via Getty Images)

Amgen Announces $650M Expansion Of US Manufacturing Network After Trump’s Pharma Tariff Announcement

Amgen said that the planned investment will support increased drug production at the company's biologics manufacturing facility in Juncos, Puerto Rico.

Bristol Myers Squibb (BMY) announced on Tuesday that a late-stage study evaluating Iberdomide in patients with relapsed or refractory multiple myeloma demonstrated a statistically significant improvement in minimal residual disease (MRD) negativity rates compared to the control arm, when combined with standard therapies.Minimal residual disease (MRD) refers to the small number of cancer cells that may remain in a patient’s body after treatment. MRD assessment has emerged as a highly sensitive and clinically meaningful tool for evaluating treatment response in multiple myeloma, a cancer of plasma cells in the bone marrow that leads to tumors in multiple bones, the company said.While MRD negativity does not necessarily mean all cancer cells are gone, it may predict improved clinical outcomes, including longer remission and survival, it added.The trial will now continue without changes to evaluate the progression-free survival (PFS), overall survival, and safety endpoints, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://news.bms.com/news/corporate-financial/2025/Bristol-Myers-Squibb-Announces-Phase-3-EXCALIBER-RRMM-Study-Evaluating-Iberdomide-in-Combination-with-Standard-Therapies-Demonstrated-a-Significant-Improvement-in-Minimal-Residual-Disease-Negativity-Rates-in-Relapsed-or-Refractory-Multiple-Myeloma/default.aspx">said</a>. Bristol Myers noted that it plans to discuss the results with health authorities.Shares of BMY traded marginally higher at the time of writing. On Stocktwits, retail sentiment surrounding <a href="https://stocktwits.com/symbol/BMY">BMY stock</a> remained within the ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:581/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_23_at_12_52_19_PM_png_34f256a597.webp" alt="BMY's Sentiment Meter and Message Volume as of 12:05 p.m. ET on Sept. 23, 2025 | Source: Stocktwits" width="581" height="60"><figcaption>BMY's Sentiment Meter and Message Volume as of 12:05 p.m. ET on Sept. 23, 2025 | Source: Stocktwits</figcaption></figure>Earlier this month, BioNTech SE (BNTX) and Bristol Myers Squibb also presented interim data from a global randomized mid-stage trial evaluating their drug Pumitamig plus chemotherapy in patients with extensive-stage small cell lung cancer. The data showed encouraging anti-tumor responses, with a positive trend in progression-free survival, or the length of time a patient with a disease lives without it worsening.According to Koyfin data, 19 out of 26 analysts covering Bristol-Myers stock rate it a ‘Hold’, six rate it ‘Buy’ or higher, while one rates it a ‘Sell.’ The average price target on the stock is $52, representing an upside of over 17% from current price levels.BMY stock is down by about 20% this year and by about 10% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/moderna-says-updated-mnexspike-covid-shot-demonstrated-rbust-immune-response-in-study/chDhMlcR35J">Moderna Says Updated mNEXSPIKE Covid Shot Demonstrated Robust Immune Response In Study</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Bristol-Myers Squibb Company logo is seen displayed on a tablet. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

Bristol Myers Announces Positive Outcomes From Multiple Myeloma Late-Stage Study

The company announced that the trial will proceed without changes to evaluate the progression-free survival, overall survival, and safety endpoints.

Shares of Kenvue slumped 6% on Monday afternoon following reports that the Trump administration is expected to unveil efforts exploring how Tylenol's active ingredient may be linked to autism.The Wall Street Journal <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.washingtonpost.com/health/2025/09/21/trump-autism-announcement-tylenol-leucovorin/">reported</a> on Monday, citing four people familiar with the matter, that federal health officials are expected to raise concerns about pregnant women using acetaminophen, the active ingredient in Tylenol. They plan to warn pregnant women against using Tylenol early or unless they have a fever, sources told WSJ.Officials also intend to tout a drug called Leucovorin as a potential autism treatment, the report said. Leucovorin is a prescription medication typically used in cancer treatment to counter the harmful side effects of other drugs.White House press secretary Karoline Leavitt, however, urged people to await an announcement today from President Trump at a press briefing.“...before you jump to conclusions based on reports that the White House has not even confirmed, I would encourage everyone in this room to go into the four o'clock announcement with some critical thinking skills and with some open ears to actually listen to what the President and his team of outsiders have to say about this. And there will be a number of things that will be announced and discussed,” she said.Tylenol is made by McNeil Consumer Healthcare, a division of Kenvue, though other companies also sell acetaminophen-based products. It is widely used as a pain reliever, including by pregnant women.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/KVUE">KVUE stock</a> jumped from ‘bearish’ to ‘bullish’ over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:574/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_22_at_2_12_39_PM_png_4b40cf5a25.webp" alt="KVUE's Sentiment Meter and Message Volume as of 2:12 p.m. ET on Sept. 22, 2025 | Source: Stocktwits" width="574" height="61"><figcaption>KVUE's Sentiment Meter and Message Volume as of 2:12 p.m. ET on Sept. 22, 2025 | Source: Stocktwits</figcaption></figure>Trump, speaking at a memorial for conservative activist Charlie Kirk on Sunday, also touted a big announcement pertaining to autism. “Tomorrow we’re going to have one of the biggest announcement[s] … medically, I think, in the history of our country,” he said, as reported by WSJ. “I think you’re going to find it to be amazing. I think we found an answer to autism.”Earlier this month, it was reported that Kenvue Inc. reportedly <a href="https://stocktwits.com/news-articles/markets/equity/tylenol-kenvue-met-rfk-jr-to-keep-off-autism-list/chw8MshRdDV">met</a> with the U.S. Health Secretary Robert F. Kennedy Jr. in a bid to keep the over-the-counter painkiller off a list of treatments causing autism.“We believe independent, sound science clearly shows that taking acetaminophen does not cause autism. We strongly disagree with any suggestion otherwise and are deeply concerned with the health risk this poses for expecting mothers,” Kenvue <a href="https://stocktwits.com/news-articles/markets/equity/kenvue-jnj-retail-traders-cautious-as-health-officials-plan-to-announce-tylenol-links-to-autism/chDQOxLR3cI">told</a> WSJ in a statement. Autism spectrum disorder (ASD) is a complex developmental condition involving persistent challenges with social communication, restricted interests, and repetitive behavior.KVUE stock is down by 20% this year and by about 25% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lyft-awarded-with-yet-another-price-target-hike-after-waymo-partnership/chDQu3aR32s">Lyft Awarded With Yet Another Price Target Hike After Waymo Partnership</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Kenvue logo is seen displayed on a smartphone screen. U.S. health officials will hold a press conference on autism, which is expected to link Kenvue's Tylenol to the disease. (Illustration by Thomas Fuller/Getty Images)

Kenvue Shares Drop Ahead Of Trump’s ‘Biggest Announcement’ On Autism: Reports Say Administration To Link Tylenol With Risk Of Disease

The Wall Street Journal reported on Monday, citing four people familiar with the matter, that federal health officials are expected to raise concerns about pregnant women using acetaminophen, the active ingredient in Tylenol.

Darden CFO Raj Vennam said the significant step down in traffic during July, led to the firm’s first quarter earnings being lower than expected

Darden Restaurants Sees Slew Of Price Target Cuts As Rising Costs Cloud Profit Outlook

Wells Fargo lowered the firm's price target on Darden to $200 from $225, noting that Darden’s comparable sales were good, but the weak flow-through is a pinch point due to rising beef costs and value investments.

European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted two positive opinions for Merck’s (MRK) blockbuster cancer drug Keytruda, the company said on Friday.While one of the opinions recommends approval for a new subcutaneous route of administration and a new solution form for injection for Keytruda, the other recommends approval for the drug in treating locally advanced head and neck squamous cell carcinoma, Merck <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.merck.com/news/merck-receives-two-positive-eu-chmp-opinions-for-keytruda-pembrolizumab-for-subcutaneous-sc-administration-and-for-new-indication-for-earlier-stage-head-and-neck-cancer/">said</a>.The committee’s recommendations will now be reviewed by the European Commission. Final decisions on marketing authorization in the European Union, Iceland, Liechtenstein, and Norway are expected in the fourth quarter.Shares of the company rose marginally in Friday’s pre-market session. On Stocktwits, retail sentiment about <a href="https://stocktwits.com/symbol/MRK">MRK stock</a> stayed within the ‘bearish’ territory over the past 24 hours, while message volume fell from ‘normal’ to ‘low’ levels.If approved for under-the-skin administration by a healthcare provider, the solution form for injection of Keytruda will be marketed in the European Union as Keytruda SC, the company said. It could be administered in one minute every three weeks or in two minutes every six weeks, offering an alternative to intravenous infusion.“If approved, we believe KEYTRUDA SC has the potential to provide meaningful benefits to patients and providers in Europe because it can offer a shorter administration time compared to KEYTRUDA and the option to receive treatment in additional health care settings,” said Marjorie Green, senior vice president and head of oncology at Merck Research Laboratories. CHMP’s positive opinion applies to all Keytruda indications approved for adult patients in Europe.An application seeking approval of subcutaneous Keytruda is currently under review in the U.S. as well. The U.S. Food and Drug Administration is expected to decide on the application by September 23.The second CHMP opinion recommends approval of Keytruda as treatment of resectable locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Head and neck cancer describes several different tumors that develop in or around the throat, larynx, nose, sinuses, and mouth. It is estimated that there were more than 947,200 new cases of head and neck cancer diagnosed globally and more than 482,400 deaths from the disease in 2022, Merck said.Keytruda is Merck’s best-selling drug. In the second quarter, the company reported sales of $8 billion from Keytruda, representing a 9% year-over-year growth.MRK stock is down 18% this year and approximately 30% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dow-futures-edge-lower-ahead-of-trump-xi-call/chD3b7SR3Rq">Dow Futures Edge Lower As Investors Watch Out For Trump-Xi Call: FDX, UPS, LEN, INTC Among Stocks To Watch</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Medicine pill is seen with Merck logo displayed on a screen in the background in this illustration photo taken in Poland on November 5, 2021. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

Merck Says EMA Committee Adopted Two Positive Opinions For Expanding Use Of Cancer Drug Keytruda

While one of the opinions recommends approval for a new subcutaneous route of administration for Keytruda, the other recommends approval for the drug in treating locally advanced head and neck squamous cell carcinoma, according to Merck. 

Meta Platforms (META) Chief Product Officer Chris Cox reportedly said that smart glasses will be the future of computing devices.According to a CNBC report on Thursday, Cox said in an interview, “We talk to them, we will see with them, we will use gestures the same way we interact with each other to interact with our computers.”“The interfaces will get more natural, and so we certainly believe that the next really important wearable technology is going to be a pair of glasses,” Cox told CNBC.Retail sentiment about the stock improved to ‘extremely bullish’ from ‘bullish’ territory a day ago, with chatter at ‘high’ levels, according to data from Stocktwits. Shares of the company were up nearly 1% during midday trading.On Wednesday, Mark Zuckerberg unveiled the Meta Ray-Ban Display AI glasses at the Meta Connect 2025 conference. Zuckerberg noted that these were the advanced AI glasses to date, featuring a full-color, high-resolution display. The company said that each pair comes with its own Meta Neural Band, an EMG wristband that translates the signals created by human muscles, such as subtle finger movements, into commands for the glasses.Meta said that the price of the glasses starts at $799, which includes both the glasses and the Meta Neural Band. Meta Ray-Ban Display will hit shelves September 30 at limited brick-and-mortar retailers in the U.S., the company said. These retailers would be Best Buy, Sunglass Hut, and Ray-Ban Stores.Cox, on Thursday, told CNBC that users will be able to record videos and also send messages via voice or physically using handwriting gestures on their knee.Shares of <a href="https://stocktwits.com/symbol/META">Meta</a> have gained nearly 34% this year and increased by 40% over the last 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/darden-flags-q2-profit-slowdown-amid-surging-beef-costs/chD2bM4R3b1">Darden Flags Q2 Profit Slowdown Amid Surging Beef Costs, CFO Says Price Spike Is Unsustainable</a>

The Meta Ray-Ban smart glasses are exhibited in Matte Black and Dusty Blue colors during the Mobile World Congress 2025 in Barcelona, Spain, on March 5, 2025. 

Meta’s Chief Product Officer Has An Interesting Take On Smart Glasses – More Details Inside

In an interview with CNBC, Cox stated that humans communicate with them, they see with them, and use gestures in the same way they interact with each other to interact with computers.

Darden Restaurants’ (DRI) Chief Financial Officer, Raj Vennam, stated that the company has reaffirmed its full-year earnings per share (EPS) forecast and anticipates the lowest year-over-year EPS growth to occur in the second quarter, driven by a significant increase in beef costs and a measured approach to pricing these costs.“There's been a significant spike in beef costs recently, especially tenders and rib eyes. We don't believe these price levels are sustainable,” Vennam said on a post-earnings call.He added that due to the significant price increase, the company was starting to see “some demand destruction in retail.” “I guess really the big picture, beef is the biggest variable here. The other component here where you're seeing a higher inflation is on seafood, primarily due to the tariffs on shrimp,” stated Vennam.Darden maintained its fiscal 2026 adjusted EPS forecast to be between $10.50 and $10.70. The company now expects annual sales growth to be between 7.5% and 8.5%, compared with the previous forecast of 7% to 8% increase.Retail sentiment on <a href="https://stocktwits.com/symbol/DRI">Darden</a> remained unchanged in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels, according to data from Stocktwits. Shares of the company were down 10% in early trading.<figure class="image"><img style="aspect-ratio:792/97;" src="https://news.stocktwits-cdn.com/DRI_sentiment_png_ac1a6e526e.webp" alt="DRI sentiment.png" width="792" height="97"><figcaption>DRI sentiment and message volume September 18, 2025, as of 11 am ET | Source: Stocktwits</figcaption></figure>The company reported that total sales at Olive Garden increased by 7.6%, driven by strong same-restaurant sales and traffic growth. LongHorn traffic was up about 3.2% for the quarter, and same restaurant sales for the segment rose 5.5%, Darden said.Darden’s first-quarter sales came in at $3.04 billion, in line with analysts’ expectations. Its adjusted EPS was $1.97, compared with estimates of $2.01.Shares of Darden have gained nearly 2% this year and increased by 10% over the last 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/ftc-sues-ticketmaster-live-nation-over-illegal-ticket-resale-tactics-report/chD2GVlR3bK">FTC Sues Ticketmaster, Live Nation Over ‘Illegal’ Ticket Resale Tactics: Report</a>

The exterior of a LongHorn Steakhouse restaurant is seen on December 19, 2024 in Austin, Texas. 

Darden Flags Q2 Profit Slowdown Amid Surging Beef Costs, CFO Says Price Spike Is Unsustainable

The company now expects annual sales growth to be between 7.5% and 8.5%, compared with the previous forecast of 7% to 8% increase.

The U.S. Federal Trade Commission (FTC) reportedly sued Ticketmaster and Live Nation Entertainment (LYV) regarding tactics related to “illegal” ticket resale.According to a CNBC report, a lawsuit was filed in California’s federal court, and seven states joined the complaint, including Florida, Illinois, and Virginia.The report added that the FTC wrote in the filing that these companies “tacitly worked” with scalpers, which allowed them to “unlawfully purchase” tickets and help in boosting their profits.″[Ticketmaster and Live Nation’s] illegal conduct frustrates artists’ desire to maintain affordable ticket prices that fit the needs of ordinary American families, costing ordinary fans millions of dollars every year,”&nbsp;the lawsuit stated, according to CNBC.Retail sentiment on <a href="https://stocktwits.com/symbol/LYV">Live Nation</a> dipped to ‘neutral’ from ‘bullish’ territory a day ago, with message volumes at ‘high’ levels, according to data from Stocktwits. Shares of the company were down nearly 3% during midday trading.The report added that the FTC’s lawsuit alleges Ticketmaster employs a “bait and switch” strategy, which allows it to alter the company’s advertising of ticket prices only to inflate the final cost. It also claims that the company knowingly permits brokers to exceed ticket limits for resale, violating the Better Online Ticket Sales Act.CNBC reported that the FTC alleged Ticketmaster was involved in “triple dipping” by charging fees at multiple stages, collecting fees from brokers in both the primary and secondary markets, as well as from consumers in the secondary market. The report, citing the FTC, said that the company generated $3.7 billion from resold tickets between 2019 and 2024.The report added that according to the FTC, Ticketmaster manages about 80% of major concert venues, and that between 2019 and 2024, consumers spent over $82 billion on tickets through the platform.Shares of Live Nation have gained 27% this year and jumped nearly 58% in the last 12 months.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/cracker-barrel-in-spotlight-after-slew-of-price-target-cuts/chDczFIR3bg">Cracker Barrel In Spotlight After Slew Of Price Target Cuts: Citi Says Q1 Began In A ‘Deep Traffic Hole’ Post Logo Change</a>

Live Nation CEO says momentum continues to build amid infrastructure expansion.

FTC Sues Ticketmaster, Live Nation Over ‘Illegal’ Ticket Resale Tactics: Report

According to a CNBC report, a lawsuit was filed in California’s federal court, and seven states joined the complaint, including Florida, Illinois, and Virginia.

Dimensional ETF Trust - Dimensional US High Profitability ETF

0 to 25,000

25,000 to 50,000

50,000 to 75,000

75,000 to 100,000

How many jobs did the U.S. add in September? Vote below + drop your exact prediction in the comments. 
 
*Powered by Polymarket

Current Price	$30.48
Prev Close	$30.34
Open	$30.36
Dividend Yield	N/A
50-Day Moving Average	$30.75
Beta	N/A
Avg. Volume	960,873.65
PE Ratio	N/A

52-Week High	$31.72
52-Week Low	$24.46
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

DUHP
Dimensional ETF Trust - Dimensional US High Profitability ETF

Feed

News

Sentiment

Fundamentals

Info

Latest DUHP News

DUHP Dimensional ETF Trust - Dimensional US High Profitability ETF